GGCT在膀胱尿路上皮癌中的表达及其临床意义
该研究采用免疫组化检测86例膀胱尿路上皮癌和10例正常膀胱黏膜中GGCT蛋白表达,阳性率为61.6%(53/86),GGCT表达与肿瘤最大径、病理分级和分期相关,GGCT阳性非肌层浸润性膀胱癌患者无复发生存率较低。
要点
- 86例膀胱尿路上皮癌中GGCT表达阳性率为61.6%(53/86),蛋白主要位于细胞质。
- GGCT表达与病理分级(P<0.001)、分期(P=0.020)和肿瘤最大径(P=0.025)正相关。
- 非肌层浸润性膀胱癌中T1期GGCT表达高于Ta期(P=0.034),GGCT阳性者无复发生存率较低(P=0.029)。
核心结论
- GGCT在膀胱尿路上皮癌组织中高表达,与肿瘤恶性生物学行为和进展有关,GGCT阳性的早期膀胱尿路上皮癌患者更易复发。
研究设计与样本
- 收集2011年1月至2013年5月潍坊市人民医院86例膀胱尿路上皮癌和10例癌旁正常膀胱黏膜组织,采用免疫组化染色检测GGCT蛋白表达并分析其与临床病理特征及预后的关系。
主要发现
- 86例膀胱尿路上皮癌组织中GGCT表达阳性率为61.6%(53/86),蛋白主要在肿瘤细胞细胞质中表达,部分病例细胞核中也有表达。
- GGCT蛋白表达水平与肿瘤最大径(P=0.025)、病理分级(P<0.001)和病理分期(P=0.020)有关。
- 非肌层浸润性膀胱尿路上皮癌中,T1期患者GGCT蛋白表达高于Ta期患者(P=0.034)。
- Kaplan-Meier分析显示GGCT阳性患者无复发生存率低于GGCT阴性患者,差异有统计学意义(P=0.029)。
- Cox多因素回归分析显示,肿瘤数量(OR=3.320,P=0.024)和病理分期(OR=5.029,P=0.009)是非肌层浸润性膀胱尿路上皮癌患者无复发生存的独立影响因素。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To evaluate the expression and clinical significance of γ-glutamylcyclotransferase (GGCT) in patients with bladder urothelial cell carcinoma. Methods: Immunohistochemical staining for GGCT were performed on tissue sections of 86 patients with bladder urothelial cell carcinoma and 10 normal controls, and the correlations between GGCT and clinicopathological characteristics and the prognosis were analyzed. Results: The positive rate of the expression of GGCT in 86 cases of bladder urothelial cell carcinoma was 61.6% (53/86). GGCT protein was located mainly in cancer cell cytoplasm, and it can be seen in the nucleus of the tumor cells in some cases. The level of GGCT expression was positively related to pathological classification (P<0.001), stage (P=0.020), and tumor size (P=0.025). Immunohistochemical semiquantitative analysis showed that the expression of GGCT in patients with T1 stage of non-muscle invasion bladder urothelial cell carcinoma was significantly higher than that with Ta stage (P=0.034). Kaplan-Meier analysis showed that the expression of GGCT was correlated with the recurrence-free survival in patients with non-muscle invasive bladder cancer, the recurrence-free survival rate was lower in the GGCT positive group (P=0.029). Multivariate COX regression analysis showed that the pathological stage (OR=5.029, P=0.009) and the number of tumors (OR=3.320, P=0.024)were the independent risk factors for recurrence-free survival in patients with early urothelial cell carcinoma of the bladder. Conclusions: The expression of GGCT is significantly increased in bladder urothelial cell carcinoma and is related to the malignant biological behavior and progression of tumor. Patients with GGCT positive early bladder tumor are inclined to recur. 目的: 探讨膀胱尿路上皮癌组织中γ-谷氨酰环化转移酶(GGCT)的表达及其临床意义。 方法: 收集2011年1月至2013年5月来自潍坊市人民医院的86例膀胱尿路上皮癌和10例癌旁正常膀胱黏膜组织,应用免疫组化染色方法检测GGCT蛋白的表达,并分析其与临床病理特征及预后的关系。 结果: 86例膀胱尿路上皮癌组织中GGCT表达阳性率为61.6%(53/86)。GGCT蛋白主要在肿瘤细胞的细胞质中表达,部分病例的细胞核中也有表达。GGCT蛋白的表达水平与膀胱尿路上皮癌的肿瘤最大径(P=0.025)、病理分级(P<0.001)和病理分期(P=0.020)有关。在非肌层浸润性膀胱尿路上皮癌中,T1期患者膀胱尿路上皮癌组织中GGCT蛋白的表达高于Ta期患者(P=0.034),GGCT阳性患者的无复发生存率低于GGCT阴性患者(P=0.029)。Cox多因素回归分析显示,肿瘤数量(OR=3.320,P=0.024)和病理分期(OR=5.029, P=0.009)是非肌层浸润性膀胱尿路上皮癌患者无复发生存的独立影响因素。 结论: GGCT在膀胱尿路上皮癌组织中高表达,与膀胱尿路上皮癌的恶性生物学行为和进展有关。GGCT阳性的早期膀胱尿路上皮癌患者更容易发生复发。.
引用
- Guo YS, Wu YD, Ma H, et al. [The expression of GGCT in the bladder urothelial cell carcinoma and its clinical significance]. Zhonghua Zhong Liu Za Zhi. 2021. PMID: 34794221. doi:10.3760/cma.j.cn112152-20200326-00264
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。